Vergoeding 2018-2022 voor ATC-subgroep H01CB : Somatostatine en analogen
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| H01CB02 Octreotide (Sandostatine ®) | 23.427.100 | 22.726.900 | 21.123.500 | 15.103.300 | 14.470.500 |
| H01CB03 Lanreotide (Somatuline ®) | 20.823.000 | 23.342.800 | 25.068.200 | 22.420.300 | 21.726.300 |
| H01CB05 Pasireotide (Signifor ®) | 2.271.000 | 2.429.600 | 2.433.800 | 2.262.300 | 2.362.400 |
| Totaal | 46.521.100 | 48.499.300 | 48.625.500 | 39.785.900 | 38.559.200 |